1 low risk of lymphoma in pediatric patients with inflammatory bowel disease treated using anti-tumor necrosis factor agents
Anti-Tumor Necrosis Factor (aTNF) agents are among the most effective medications used to treat pediatric inflammatory bowel diseases (pIBD). Despite their effectiveness, concerns regarding an association with lymphoma limit their use in everyday practice. We sought to determine the incidence rate and absolute risk of lymphoma in pIBD patients receiving aTNF treatment using a large, geographically diverse administrative insurance claims database.
Source: Gastroenterology - Category: Gastroenterology Authors: Matthew Egberg, Andrew Smitherman, Xian Zhang, Michael Kappelman Tags: Adverse Events Related to Therapy Source Type: research
More News: Databases & Libraries | Gastroenterology | Inflammatory Bowel Disease | Insurance | Lymphoma | Pediatrics